Incyte (INCY) executive compensation, 2026 proxy

William J. Meury, Chief Executive Officer, was paid $32.1M in 2025. The CEO-to-median-employee pay ratio was 110:1, on median employee pay of $295,914.

Filed
April 28, 2026
Annual meeting
June 8, 2026
Pay year
2025
Named executives
7
CEO total pay
$32.1M2025
CEO to median employee
110:1median $295,914
CEO pay in equity
94%$30.1M in awards
2025 Net Sales
$4.35B20% year-over-year growth
Core Business Non-Jakafi Sales
$1.26B53% increase compared to 2024
CEO Stock Awards
$27.5MIncludes sign-on performance shares
CEO Performance Share Mix
60%Of target equity value for 2025

How Meury was paid

$32.1M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary2%Stock awards86%Option awards8%Non-equity incentive4%All other compensation0%

Named executive officers

ExecutiveTotal
William J. MeuryChief Executive Officer$32,085,952
Hervé HoppenotFormer President and Chief Executive Officer$6,380,525
Pablo J. CagnoniPresident and Global Head of Research and Development$8,838,961
Mohamed IssaExecutive Vice President and Head of U.S. Commercial$10,592,782
Steven H. SteinExecutive Vice President, Chief Medical Officer and Head of Late-stage Development$6,304,172
Christiana StamoulisFormer Executive Vice President and Chief Financial Officer$4,936,550
Thomas TrayVice President, Chief Accounting Officer and Principal Financial Officer$990,368

What changed and why

  • William J. Meury joined as President and Chief Executive Officer in June 2025.
  • $4.35BTotal net sales reached $4.35 billion, representing 20% year-over-year growth.
  • 60%Performance shares comprised 60% of the CEO target equity award values for 2025.
  • $1.26BCore business sales outside of Jakafi increased 53% to $1.26 billion.
  • Hervé Hoppenot retired as President and Chief Executive Officer in June 2025.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.